Novozymes results: Acrylamide-removing, trans fat reduction and low-lactose solutions drive F&B grow
date:Oct 26, 2018
impact the EBIT margin negatively. The DKK ~30 million lower deferred income expected in 2018 relative to 2017 also reduces the reported EBIT by an identical amount.

Sales growth and productivity improvements are expected to be supportive of margins, mitigating the effects from higher input costs, says the company.

07/09 10:41